Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 231

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 231
---
 skills to serve as a member of our board of directors.

Joshua Resnick, M.D., M.B.A., has served as a member of our board of directors since December 2019. Dr. Resnick is a senior managing
director at RA Capital Management, L.P., where he previously served as a Managing Director from October 2018 to March 2023. Dr. Resnick is also a faculty member at Harvard Medical School and continues to practice medicine as an attending
physician in the Department of Emergency Medicine at Massachusetts General Hospital. Dr. Resnick has served on the boards of directors of PepGen Inc. (NASDAQ: PEPG) since November 2020, Aerovate Therapeutics, Inc. (NASDAQ: AVTE) since August
2020, as well as from October 2018 to February 2020, and Vor Biopharma Inc. (NASDAQ: VOR) since February 2019. Dr. Resnick received a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania Perelman School of
Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania. We believe Dr. Resnick’s biopharmaceutical industry and investor experience and medical background provides him with the appropriate set of skills to serve
as a member of our board of directors.

Marcella Kuhlman Ruddy, M.D., has served as a member of our board of directors since January
2025. Dr. Ruddy has over 20 years of experience in drug development. Dr. Ruddy has served as the chief medical officer of Tectonic Therapeutic, Inc. (NASDAQ: TECX) since July 2021. From June 2016 to June 2021, Dr. Ruddy served as vice president of
clinical development, immunology at Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), where she oversaw the clinical development of Dupixent. She is a trained pulmonologist who founded and led the Adult Cystic Fibrosis center at Massachusetts General
Hospital, Boston from 1999-2004 prior to starting her drug development career at Merck & Co Inc. (NYSE: MRK). Dr. Ruddy has served on the board of directors of Upstream Bio, Inc. (NASDAQ: UPB) since January 2023. Dr. Ruddy previously served on
the board of directors of Polarean, Inc. from August